Resources

If you need more information feel free to contact our Help Center

Building an AI Scientist Around the Work R&D Needs

Defining the assignments an AI scientist should complete helps R&D teams assess its capabilities, review its work and determine where scientific judgment is required.

Yiannis Kiachopoulos

October 20, 2026

Blog

Discover the latest reports, data sheets, articles, infographics, and videos on biomedical R&D and AI.

Assessing indication opportunities: one asset connected to three candidate indications.

Choosing the Next Indication Requires a Different Kind of Assessment

October 21, 2026

How evidence requirements and decision criteria evolve across indication identification, selection, and expansion.

Building an AI Scientist Around the Work R&D Needs

Yiannis Kiachopoulos

October 20, 2026

Defining the assignments an AI scientist should complete helps R&D teams assess its capabilities, review its work and determine where scientific judgment is required.

How AI is Changing Scientific Research and the Role of the Scientist

Janis Tam

September 23, 2026

Janis Tam has spent nearly five years working directly with scientists across pharmaceutical R&D as they apply AI to research questions and decision-making. With a PhD in molecular biology and a research background spanning genetics, gene regulation and neurobiology, she brings both a scientist’s perspective and first-hand experience of how researchers are adapting as AI becomes more capable.

How To Turn a Drug Pipeline Landscape into a Scientific Assessment?

Written by Stavroula Ntoufa and Jumana Badar

September 16, 2026

It is easy to look at a long list of assets and conclude that a field is crowded. Sometimes that conclusion holds, but the list often disguises important differences. The number of programs alone can be misleading.

From the Lab’s Biggest AI Skeptic to Its Advocate

Jessica Armand

August 26, 2026

Jessica Armand spent five years studying drug resistance in breast cancer and told everyone in her lab not to trust AI. Now she's an AI advocate and onboards skeptical scientists onto the Causaly platform.

How Causaly's Scientific Workflows turn weeks of competitive analysis into cited, board-ready assessments.

Anton Tcholakov

August 20, 2026

SOPs provide rigor, but manual execution limits speed and scale. Causaly’s Scientific Workflows use coordinated AI agents to deliver the same rigor with greater speed, breadth, and scalability.

Unraveling Mechanisms of Disease Pathogenesis with AI

Anna Tzani

March 6, 2024

AI-supported investigations into disease mechanisms offer a transformative approach to understand complex pathologies. By leveraging AI to unlock disease understanding, researchers can identify novel biomarkers and therapeutic targets with unprecedented precision. This not only accelerates the journey from lab to market but also enhances the efficacy and safety of new treatments.

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani

February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Exploring the Disease Pathophysiology of Rheumatoid Arthritis

Anna Tzani

February 6, 2024

Understanding the pathophysiology of a disease is pivotal in comprehending its cause and progression and facilitating the identification of novel targets for therapeutic intervention. Data-driven strategies are essential in navigating this complexity, facilitating a deeper understanding of disease pathophysiology, which can be leveraged to develop more effective treatments.

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani

January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani

January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Uncovering the Mechanism of Action of Evolocumab against PAD

Anna Tzani

January 12, 2024

Deciphering a drug’s MoA is crucial for making informed decisions in drug development, paving the way for the development of more targeted and effective therapeutic solutions. AI can revolutionize this process by facilitating knowledge discovery without bias, unveiling hidden drug-disease interactions.

ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform

Yiannis Kiachopoulos

January 28, 2025

ProQR faced challenges with bandwidth, aggressive targets, and the overwhelming growth of biomedical literature. Causaly's AI platform accelerated ProQR’s R&D by enabling faster review of publications and allowing their team to make more informed decisions. Read the case study below to learn how ProQR met their 2024 target ID goal by Q3 and achieved 5x productivity compared to using PubMed.

Enhance Your Search Sensitivity with AI: Off-Target Effects of BRAF

Anna Tzani

February 29, 2024

In contrast to conventional keyword searching techniques, Causaly’s AI can sift through and remove irrelevant data from biomedical searches, offering a more thorough and accurate understanding of entire research landscapes. This not only streamlines knowledge acquisition but ensures accuracy and precision in navigating the biomedical literature.

Leveraging AI for Scientific Knowledge Extraction

Anna Tzani

February 13, 2024

AI is transforming the analysis of extensive biomedical data, allowing pharma companies to expedite R&D processes, and cut costs. By reaching conclusions quicker, the inclusion of AI in drug development pipelines can inform decision-making, enabling the prioritization of more promising research avenues.

Search by Target Class: Enzyme Targets for Celiac Disease

Anna Tzani

January 26, 2024

The strategic prioritization of drug targets by target class can be used to streamline discovery, enabling efficient resource allocation and time-savings in early drug development, as well as a competitive edge given the variable success rates of different target classes. Prioritization of specific target classes may therefore enable investment optimization in preclinical research.

Navigating the Biomedical Literature: Insights vs. Papers

Anna Tzani

January 19, 2024

With 2 publications added to PubMed every minute, identifying therapeutic targets with traditional keyword searching is time-consuming, causes reading fatigue and is subject to bias. By machine-reading the literature, Causaly manages this data overload, extracting scientific insights rather than papers, to enable the exploration of more novel avenues.

Eliminating Bias with Human-Centric AI

Anna Tzani

January 9, 2024

Traditional keyword searching can miss crucial information, skewing representations of research landscapes before reading even begins. Instead, Causaly’s human-centric AI can extract all targets for a given disease without bias, uncovering scientific insights, rather than just papers.

Aiding Drug Repurposing Investigations with AI

Anna Tzani

February 23, 2024

Drug repurposing offers a cost-effective and efficient pathway to discovery new therapeutic uses for existing treatments. AI can advance this process by rapidly analyzing large-scale biomedical data and scientific texts to identify drug-disease relationships, opening up avenues for treatments in unexplored indications.

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani

February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

AI-Powered Drug Discovery: Identifying Safety Red Flags

Anna Tzani

January 30, 2024

Unmanageable toxicity accounts for 30% of clinical drug development failures and can cause severe side effects and potential harm to patients. Download our report to see how AI-powered drug discovery can help mitigate late-stage clinical failures and market withdrawals.

Comparison of Safety Biomarkers for Chemotherapeutics

Anna Tzani

February 9, 2024

The identification and utilization of safety biomarkers plays a key role in mitigating toxicity risks and reducing costs in drug development, thereby accelerating the delivery of safe and effective drugs to patients. AI can streamline the identification of relevant biomarkers from the ever-growing biomedical literature, offering insights into drug resistance and toxicity.

Challenging the Status Quo: A Biomarker Use Case

Anna Tzani

January 24, 2024

Traditional keyword searching is highly inefficient, subject to bias and is not always comprehensive, providing limited potential for knowledge discovery and hypothesis generation. This selective approach introduces a bias towards familiar areas of expertise, which can lead to missed opportunities for novel insights and innovations. This is where AI comes in.

Biomarkers of Treatment Response in Liver Cancer

Anna Tzani

December 7, 2023

Biomarkers serve as objective measures of treatment response to guide patients towards the most appropriate therapies. Yet, in the era of big data, pinpointing promising biomarkers remains a challenging endeavor. AI is revolutionizing translational medicine by improving the efficiency and accuracy of biomarker identification.

Expedite Biomarker Discovery with Human-Centric AI

Anna Tzani

December 4, 2023

Biomarkers are pivotal throughout drug development, from discovery to market, playing key roles in unravelling drug mechanisms, providing prognostic insights and assessing treatment efficacy. Despite the clinical promise, biomarker development is challenging. There are substantial obstacles, from disease heterogeneity and rigorous validation requirements to the inability to extract meaningful biomarker insights from extensive biological data.

News

The latest news and updates from Causaly.

news

Causaly is Now Available in Microsoft Copilot

September 17, 2026

Enterprise scientists and knowledge workers can now access Causaly's scientifically grounded research directly inside of Microsoft 365 Copilot, helping users turn evidence into decision-ready intelligence

news

Causaly and Syneos Health Partner to Raise the Scientific Intensity of Clinical Research

Team Causaly

August 18, 2026

Collaboration embeds evidence-grounded agentic AI into scientific workflows across Syneos Health,accelerating research while strengthening scientific rigor, consistency, and sponsor value

news

Causaly and Sage Bring Full-Text Scientific Literature into AI-Powered Drug Discovery Research

Team Causaly

July 29, 2026

Partnership allows Causaly AI agents to access and read full-text of Sage journal articles and deliver the most relevant insights directly within the Causaly platform, helping mutual customers unlock deeper evidence from their existing institutional licenses

news

Microsoft and Causaly Integration Accelerates Biopharma R&D Through AI-Driven Scientific Reasoning

June 29, 2026

The technical significance of this integration lies in its ability to move beyond simple ‘horizontal’ AI tools.

news

Causaly, Microsoft link computation and scientific reasoning

June 29, 2026

The workflow aims to help biopharma teams assess targets, biomarkers, safety and mechanism questions with cited evidence.

news

Causaly and Microsoft target one of drug discovery’s most expensive decisions: which target to pursue

June 29, 2026

What compresses is the knowledge work, the analytical layer that sits on a program’s critical path: building a baseline of what’s known, drafting protocols, reviewing safety, selecting candidates.

Events and Webinars

Our events and webinars on demand and dig deeper into the next era of scientific research.

Webinar

Causaly Dissected: Delivering Faster, More Credible Evidence for Every Client Study

September 30, 2026

In this episode of Causaly Dissected our scientists take one of the most time pressured workflows in a CRO, building a credible scientific response to a sponsor RFP, and walk through it live in Causaly.

Watch now

Webinar

Causaly Dissected: Clinical Development - When the Trial is Running

September 9, 2026

In this episode of Causaly Dissected, our scientists walk through the evidence workflows behind clinical development, from safety evaluation and biomarker review to signal monitoring and NDA and BLA support.

Watch now

Webinar

Causaly Dissected: Clinical Development - Building the Case Before the Trial

August 12, 2026

In this episode of Causaly Dissected our scientists take one of the highest stakes workflows in Clinical Development, building the evidence case before a single patient is enrolled, and walk through it live in Causaly.

Watch now

Webinar

Evidence at the Speed of Science: How Leading Pharma Is Putting AI to Work in R&D

July 30, 2026

Takeda's Head of Computational and Systems Biology on how his team applies AI to indication expansion, mechanism of action work, and everyday R&D decisions.

Watch now

Webinar

Causaly Dissected: Reducing Scientific Uncertainty in Translational Medicine

July 8, 2026

In this episode of Causaly Dissected, our scientists take one of the highest-stakes TxMed workflows, target validation and translational evidence synthesis, and walk through it live in Causaly.

Watch now

Webinar

Automate Your Research Workflows - From Question to Confident Decision

No items found.

June 17, 2026

Join us for an exclusive look at Scientific Workflows by Causaly. The governed agentic automation solution moving life sciences R&D from scientific intelligence to scientific execution.

Watch now